EAU 2020 Bladder Cancer

Viewing 1-15 of 15 articles

EAU 2020: Frailty and Cognitive Assessment in Patients Diagnosed with Muscle-Invasive Bladder Cancer

EAU 2020: Five Things I Wish I Would Have Known Earlier in My Career: Lessons from the Mentors - Bladder Cancer

EAU 2020: Perioperative Therapy for Urothelial Cancer: Should We Sequence All Urothelial Cancer Patients?

EAU 2020: The Future of Personalized Treatment: Test the Tumor for a Response

EAU 2020: Novel Urothelial Cancer Treatment Beyond PD-1/PD-L1 Inhibition

EAU 2020: Different Bladder Cancer Genotypes: New Treatment Options

EAU 2020: Treatment Options for Elderly Patients with Muscle-Invasive Bladder Cancer

EAU 2020: Perioperative Therapy for Urothelial Cancer: Chemotherapy Remains Standard of Care

EAU 2020: Urinary Markers in Low-Grade Non-Muscle Invasive Bladder Cancer: Ready to Stop Cystoscopies

EAU 2020: Immunotherapy and Beyond: New Options for Non-Muscle Invasive Bladder Cancer

EAU 2020: Perioperative Therapy for Urothelial Cancer: PD-1/PD-L1 Inhibitors are Replacing Perioperative Chemotherapy

EAU 2020: Recurrence Risk in Patients with High Grade Non-Muscle Invasive Bladder Carcinoma in the Randomised Phase III Clinical Trial ‘NIMBUS’ Stratified for EORTC and CUETO Risk Categories. A contemporary Trend to Less Recurrences?

EAU 2020: Results from the phase III study of Nadofaregene Firadenovec: Safety and Efficacy in Patients with High-grade, BCG-unresponsive Non-Muscle Invasive Bladder Cancer

EAU 2020: Early Cystectomy in High-Risk Non-Muscle Invasive Bladder Cancer: A Standard

EAU 2020: Definition of Very High-Risk and Refractory Non-Muscle Invasive Bladder Cancer

email news signup